Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 807-811

  Hanif, W ^a   Malik, W ^b   Hassanein, M ^c   Kamal, A ^b   Geransar, P ^d   Andrews, C ^d   Azam, M ^b   Barnett, A H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^d Novartis Pharmaceuticals UK Limited   (United Kingdom)

Author keywords

Fasting; Hypoglycaemic events; Muslim patients; Ramadan; Treatment adherence; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY;

ADAMANTANE; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; SULFONYLUREA COMPOUNDS;

EID: 84880282824     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.803054     Document Type: Article

References (11)

1. Al-Arouj M, Boguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305-11
2. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11
3. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabetes Med 2008;25:245-54
4. Aadil N, Houti IE, Moussamih S. Drug intake during Ramadan. BMJ 2004;329:778-82
5. Lawton J, Ahmad N, Hallowell N, et al. Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: qualitative study. BMJ 2005;330:1247
6. Ahmedani MY, Haque MS, Basit A, et al. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med 2012;29:709-15
7. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
8. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-9
9. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367-74
10. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446-50
11. Al Sifri S, Basiounny IA, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011;65:1132-40